In recent years, areas of particular interest have included:
Long-acting analogs of PTH are being developed as possible therapies for primary hypoparathyroidism in people. Studies of FGF23, the recently described regulator of phosphate homeostasis, have involved a series of clinical and basic investigative studies. Clinical studies have also focused on the roles of androgens and estrogens on bone and other targets in males, the various roles of vitamin D and an analysis of the effectiveness of current therapies for primary hypoparathyroidism. New clinical work examines the microarchitecture of human bone noninvasively. This work is funded primarily by the National Institutes of Health (NIH), by NIH program projects and by pharmaceutical company support.
Our investigators range from bench scientists to translational researchers. See below for more information about our investigators.
Recent research accomplishments in the Endocrine Unit include:
Postdoctoral Fellow/Research Scientist PositionsWe do not have any open positions at this time.
Please see complete listings on individual investigator profiles.
Hours: 9:00 am - 4:30 pm, M-F
Public Transportation Access: yes
Disabled Access: yes
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care